ADB-CHMINACA (also known as MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication.It was identified in cannabinoid blends in Japan in early 2015
It’s cannabinoid and analog of ADB-Fubinaca
Other name: MAB-AB-Chminaca, MA-Chminaca
IUPAC name: methyl 2-(1-(cyclohexylmethyl)-1H-indazole-3-carboxamido)-3-methylbutanoate
CAS number: 932182-81-2
Purity: 99,3% min
Appearance: white powder
The physiological and toxicological properties of this compound are not known. This product is intended for research and forensic purposes.